SE442011B - N-(4-alkanoyloxifenyl)-all-trans-retinamid och komposition for forhindrande av framkallning av kancer i epitelial vevnad - Google Patents
N-(4-alkanoyloxifenyl)-all-trans-retinamid och komposition for forhindrande av framkallning av kancer i epitelial vevnadInfo
- Publication number
- SE442011B SE442011B SE7906365A SE7906365A SE442011B SE 442011 B SE442011 B SE 442011B SE 7906365 A SE7906365 A SE 7906365A SE 7906365 A SE7906365 A SE 7906365A SE 442011 B SE442011 B SE 442011B
- Authority
- SE
- Sweden
- Prior art keywords
- retinamide
- trans
- composition
- prevention
- tissue
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 4
- 230000002265 prevention Effects 0.000 title description 4
- 238000000034 method Methods 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 210000000981 epithelium Anatomy 0.000 claims description 8
- 229940100552 retinamide Drugs 0.000 claims description 8
- 238000011161 development Methods 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000006186 oral dosage form Substances 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 8
- 229930002330 retinoic acid Natural products 0.000 description 8
- 229960001727 tretinoin Drugs 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 150000004492 retinoid derivatives Chemical class 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 210000003437 trachea Anatomy 0.000 description 5
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 4
- -1 Vitamin A Hydrocarbon Chemical class 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960005280 isotretinoin Drugs 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010054949 Metaplasia Diseases 0.000 description 3
- 230000003780 keratinization Effects 0.000 description 3
- 230000015689 metaplastic ossification Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229960000342 retinol acetate Drugs 0.000 description 3
- 235000019173 retinyl acetate Nutrition 0.000 description 3
- 239000011770 retinyl acetate Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- DIKPQFXYECAYPC-UHFFFAOYSA-N N-butyl-N-(4-hydroxybutyl)nitrosamine Chemical compound CCCCN(N=O)CCCCO DIKPQFXYECAYPC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000718541 Tetragastris balsamifera Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- IDMGVRDNZFQORW-JWBAUCAFSA-N axerophthene Chemical compound C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C IDMGVRDNZFQORW-JWBAUCAFSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012822 chemical development Methods 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/929,093 US4310546A (en) | 1978-07-31 | 1978-07-31 | Novel retinoids and their use in preventing carcinogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7906365L SE7906365L (sv) | 1980-02-01 |
| SE442011B true SE442011B (sv) | 1985-11-25 |
Family
ID=25457311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7906365A SE442011B (sv) | 1978-07-31 | 1979-07-25 | N-(4-alkanoyloxifenyl)-all-trans-retinamid och komposition for forhindrande av framkallning av kancer i epitelial vevnad |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4310546A (fr) |
| AT (1) | AT367032B (fr) |
| BE (1) | BE877976A (fr) |
| CA (1) | CA1108170A (fr) |
| CH (1) | CH644845A5 (fr) |
| DE (1) | DE2930923A1 (fr) |
| DK (1) | DK324279A (fr) |
| FR (1) | FR2432509A1 (fr) |
| GB (1) | GB2026493B (fr) |
| IE (1) | IE48304B1 (fr) |
| IT (1) | IT1162414B (fr) |
| NL (1) | NL7905893A (fr) |
| NO (1) | NO149999C (fr) |
| SE (1) | SE442011B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5456663A (en) * | 1984-05-25 | 1995-10-10 | Lemelson; Jerome H. | Drugs and methods for treating diseases |
| US4665098A (en) * | 1985-03-28 | 1987-05-12 | Mcneilab, Inc. | Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability |
| WO1989005854A1 (fr) * | 1987-12-16 | 1989-06-29 | Institut Pasteur | Nouveau gene associe au recepteur d'hormones steroidiques/thyroidiennes, qui est exprime de façon inappropriee dans le carcinome hepatocellulaire de l'homme et qui constitue un recepteur d'acide retinoique |
| US5235076A (en) * | 1991-05-28 | 1993-08-10 | University Of Hawaii | Azulenic retinoid compounds, compositions and methods |
| US5849595A (en) * | 1992-10-05 | 1998-12-15 | Alfano; Robert R. | Method for monitoring the effects of chemotherapeutic agents on neoplasmic media |
| US5716982A (en) * | 1995-06-07 | 1998-02-10 | Institute Of Materia Medica, An Institute Of The Chinese Academy Of Medical Sciences | Retinoids and methods of use of same |
| US5703130A (en) * | 1995-06-07 | 1997-12-30 | Institute Of Materia Medica, An Institute Of The Chinese Academy Of Medical Sciences | Chalcone retinoids and methods of use of same |
| US5968940A (en) * | 1995-06-08 | 1999-10-19 | Institute Of Materia Medica | Retinoids and methods of use of same |
| WO2002096857A1 (fr) * | 2001-05-29 | 2002-12-05 | Chebigen Co., Ltd. | Nouveaux derives de retinoide, procedes de preparation de ces composes et composition pharmaceutique anti-cancer renfermant lesdits composes |
| KR100508627B1 (ko) * | 2001-05-29 | 2005-08-17 | (주)케비젠 | 신규한 레티노이드 유도체 및 이의 제조방법 및 그화합물을 함유한 항암제 조성물 |
| WO2005072091A2 (fr) * | 2003-12-09 | 2005-08-11 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Procedes d'inhibition des infections a vih et autres infections virales par modulation du metabolisme des ceramides |
| PL380611A1 (pl) * | 2004-02-17 | 2007-02-19 | President And Fellows Of Harvard College | Postępowanie z zaburzeniami oftalmologicznymi, włącznie ze zwyrodnieniem plamki |
| US7566808B2 (en) | 2004-02-17 | 2009-07-28 | President And Fellows Of Harvard College | Management of ophthalmologic disorders, including macular degeneration |
| EA011154B1 (ru) | 2004-12-08 | 2009-02-27 | Сирион Терапьютикс, Инк. | Композиции для лечения ретинол-ассоциированных заболеваний |
| KR20060094745A (ko) * | 2005-02-25 | 2006-08-30 | (주)나노하이브리드 | 층상형 금속 수산화물과 레티노익산의 혼성체를 함유하는암치료용 약학적 조성물 |
| TW200829269A (en) * | 2007-01-12 | 2008-07-16 | Koyo Internat Holding Corp | Methods for the cultivation of DC/D-CIK cells and applications |
| CN101591280B (zh) * | 2008-05-30 | 2012-08-22 | 安徽医科大学 | 具有肿瘤诱导分化作用的类维甲酸衍生物及其药物组合物与用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH529742A (de) * | 1970-02-02 | 1972-10-31 | Hoffmann La Roche | Verfahren zur Herstellung von Vitamin-A-Säureamiden |
| DE2300107C2 (de) * | 1973-01-03 | 1982-03-11 | Basf Ag, 6700 Ludwigshafen | Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen |
| US4108880A (en) * | 1975-11-03 | 1978-08-22 | Johnson & Johnson | Esters of retinoic acid |
-
1978
- 1978-07-31 US US05/929,093 patent/US4310546A/en not_active Expired - Lifetime
-
1979
- 1979-05-15 GB GB7916839A patent/GB2026493B/en not_active Expired
- 1979-06-14 CA CA329,779A patent/CA1108170A/fr not_active Expired
- 1979-07-25 SE SE7906365A patent/SE442011B/sv not_active IP Right Cessation
- 1979-07-27 IT IT49884/79A patent/IT1162414B/it active
- 1979-07-30 BE BE0/196526A patent/BE877976A/fr not_active IP Right Cessation
- 1979-07-30 NO NO792507A patent/NO149999C/no unknown
- 1979-07-30 DE DE19792930923 patent/DE2930923A1/de not_active Ceased
- 1979-07-30 AT AT0522979A patent/AT367032B/de not_active IP Right Cessation
- 1979-07-30 FR FR7919566A patent/FR2432509A1/fr active Granted
- 1979-07-31 NL NL7905893A patent/NL7905893A/nl not_active Application Discontinuation
- 1979-07-31 CH CH705479A patent/CH644845A5/de not_active IP Right Cessation
- 1979-07-31 DK DK324279A patent/DK324279A/da not_active Application Discontinuation
- 1979-08-08 IE IE1441/79A patent/IE48304B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| GB2026493A (en) | 1980-02-06 |
| GB2026493B (en) | 1982-09-29 |
| IE791441L (en) | 1980-01-31 |
| IT1162414B (it) | 1987-04-01 |
| IT7949884A0 (it) | 1979-07-27 |
| SE7906365L (sv) | 1980-02-01 |
| FR2432509B1 (fr) | 1984-03-30 |
| DK324279A (da) | 1980-02-01 |
| DE2930923A1 (de) | 1980-02-21 |
| NO149999B (no) | 1984-04-24 |
| AT367032B (de) | 1982-05-25 |
| IE48304B1 (en) | 1984-11-28 |
| FR2432509A1 (fr) | 1980-02-29 |
| BE877976A (fr) | 1980-01-30 |
| CA1108170A (fr) | 1981-09-01 |
| US4310546A (en) | 1982-01-12 |
| NO792507L (no) | 1980-02-01 |
| ATA522979A (de) | 1981-10-15 |
| CH644845A5 (de) | 1984-08-31 |
| NO149999C (no) | 1984-08-01 |
| NL7905893A (nl) | 1980-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE442011B (sv) | N-(4-alkanoyloxifenyl)-all-trans-retinamid och komposition for forhindrande av framkallning av kancer i epitelial vevnad | |
| US4323581A (en) | Method of treating carcinogenesis | |
| US5736576A (en) | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity | |
| US7915303B2 (en) | Glycopyrronium salts and their therapeutic use | |
| EP0140243B1 (fr) | Phénoxypropanolamines | |
| US3809714A (en) | Novel ester of ((methylamino)methyl) benzyl alcohol | |
| EP0527458A1 (fr) | Nouveaux dérivés de 3,5-di-tert.butyl-4-hydroxyphényl, procédé pour leur préparation et compositions pharmaceutiques | |
| KR850000065B1 (ko) | 린코마이신 및 클린다마이신의 제조방법 | |
| IL193774A (en) | Pharmaceutical compositions containing a 3,5-seco-4-norcholestane derivative | |
| EP1094055B1 (fr) | Nouveaux derives vinylbenzene | |
| EP0051819A2 (fr) | Dérivés tétra substitués de benzène, leur préparation et préparations pharmaceutiques les contenant | |
| EP4129978A1 (fr) | Nanoparticules comprenant des dimères de médicament et utilisation associée | |
| CA2373603A1 (fr) | Composes diphenylethylene innovants | |
| US4675341A (en) | [(5,6-dichloro-3-oxo-9a-propyl-2,3,9,9a-tetrahydrofluoren-7-yl)oxy]ethanol and its derivatives | |
| BR9814053B1 (pt) | diésteres lipofìlicos de agentes de quelação. | |
| US4719310A (en) | Ester and amide substituted (2,3-dihydro-4-(3-oxo-1-cyclohexen-1-yl)phenoxy)alkanoic acids and their salts | |
| DE60013818T2 (de) | Quaternäre ammoniumverbindungen, verfahren zu deren herstellung und deren pharmazeutische verwendung | |
| US4950686A (en) | Anti-mycoplasma agent | |
| EP0004522B1 (fr) | Nouveaux composés analogues aux dilignols, composés analogues aux dilignols utilisable dans le traitement des maledies hépatiques et compositions pharmaceutiques les contenant | |
| EP0006217B1 (fr) | Acides aminés substitués, leur utilisation et leur préparation et médicaments les contenant | |
| US5698585A (en) | Pharmaceutical preparation for prevention and/or treatment for cataract | |
| JP2000514412A (ja) | 神経毒性損傷の処置のためのバックミンスターフラーレンの使用 | |
| DE10201228A1 (de) | 10-Benzyliden-9(10H)anthracenone als neue Inhibitoren der Tubulinpolymerisation | |
| LU84062A1 (fr) | Esters de mercaptoacyl-carnitines,procede pour leur preparation et leurs utilisations therapeutiques,notamment dans le traitement des intoxications et des brulures et en tant qu'agents mucolytiques | |
| US4472424A (en) | Esters of 2-thenoylmercaptopropionylglycine with substituted hydroxybenzenes, process for their preparation and pharmaceutical compositions containing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 7906365-7 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 7906365-7 Format of ref document f/p: F |